CD8A and liver cancer: Our analysis showed that the percentages of CD4+ and the CD4+/CD8+ ratio were increased in the rAd-p53 combined with TACE group, suggesting that the immune function of liver cancer patients was improved after rAd-p53 treatment, so we believe that rAd-p53 also has great potential in the immunotherapy of liver cancer.